Gossamer Bio, Inc. (GOSS)
Largest Insider Buys in Sector
GOSS Stock Price History Chart
GOSS Stock Performance
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Insider Activity of Gossamer Bio, Inc.
Over the last 12 months, insiders at Gossamer Bio, Inc. have bought $324,442 and sold $53,578 worth of Gossamer Bio, Inc. stock.
On average, over the past 5 years, insiders at Gossamer Bio, Inc. have bought $969,539 and sold $356,034 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hasnain Faheem (President & CEO) — $1M. Giraudo Bryan (COO/CFO) — $118,220. Smith Robert Paul JR (Chief Commercial Officer) — $15,050.
The last purchase of 372,000 shares for transaction amount of $250,282 was made by Hasnain Faheem (President & CEO) on 2024‑06‑21.
List of Insider Buy and Sell Transactions, Gossamer Bio, Inc.
| 2024-06-24 | Sale | Chief Medical Officer | 1,908 0.0007% | $0.66 | $1,260 | +10.16% | ||
| 2024-06-21 | President & CEO | 372,000 0.2168% | $0.67 | $250,282 | +40.00% | |||
| 2024-06-18 | COO/CFO | 100,000 0.0512% | $0.59 | $59,110 | +67.65% | |||
| 2024-06-17 | Chief Commercial Officer | 25,000 0.013% | $0.60 | $15,050 | +74.72% | |||
| 2024-03-27 | Sale | EVP, Tech Ops and Admin | 6,430 0.0028% | $1.16 | $7,430 | -26.60% | ||
| 2024-03-27 | Sale | President & CEO | 23,172 0.0101% | $1.16 | $26,773 | -26.60% | ||
| 2024-03-27 | Sale | COO/CFO | 6,430 0.0028% | $1.16 | $7,431 | -26.60% | ||
| 2024-03-18 | Sale | Chief Medical Officer | 4,018 0.0017% | $1.33 | $5,342 | -36.08% | ||
| 2024-03-18 | Sale | EVP, Regulatory Affairs | 4,018 0.0017% | $1.33 | $5,343 | -36.08% | ||
| 2023-11-15 | director | 32,000 0.0139% | $0.79 | $25,213 | +11.11% | |||
| 2023-11-13 | COO/CFO | 200,000 0.0795% | $0.56 | $112,880 | +40.06% | |||
| 2023-06-22 | Sale | Chief Medical Officer | 1,814 0.0018% | $1.29 | $2,340 | -34.29% | ||
| 2023-04-04 | COO/CFO | 55,000 0.0583% | $1.02 | $56,095 | +3.45% | |||
| 2023-03-16 | Sale | Chief Medical Officer | 7,563 0.0083% | $1.10 | $8,304 | 0.00% | ||
| 2023-03-16 | Sale | Chief Scientific Officer | 6,029 0.0066% | $1.10 | $6,620 | 0.00% | ||
| 2023-03-16 | Sale | EVP, Regulatory Affairs | 7,564 0.0083% | $1.10 | $8,305 | 0.00% | ||
| 2022-10-24 | Sale | Chief Medical Officer | 4,757 0.0056% | $12.07 | $57,431 | -88.94% | ||
| 2022-10-24 | Sale | Chief Scientific Officer | 4,876 0.0058% | $12.07 | $58,868 | -88.94% | ||
| 2022-10-24 | Sale | EVP, Regulatory Affairs | 4,757 0.0056% | $12.07 | $57,431 | -88.94% | ||
| 2022-07-15 | President & CEO | 138,696 0.099% | $7.21 | $999,998 | -79.92% |
Insider Historical Profitability
| Hasnain Faheem | President & CEO | 5408073 2.3866% | $0.76 | 4 | 2 | <0.0001% |
| Christian Waage | EVP, Tech Ops and Admin | 585934 0.2586% | $0.76 | 4 | 3 | <0.0001% |
| Giraudo Bryan | COO/CFO | 480010 0.2118% | $0.76 | 9 | 3 | <0.0001% |
| Aranda Richard | Chief Medical Officer | 196891 0.0869% | $0.76 | 0 | 8 | |
| Peterson Caryn | EVP, Regulatory Affairs | 49833 0.022% | $0.76 | 0 | 5 | |
| Smith Robert Paul JR | Chief Commercial Officer | 25000 0.011% | $0.76 | 1 | 0 | |
| Omega Fund V, L.P. | 10 percent owner | 6553416 2.892% | $0.76 | 0 | 8 | |
| Gujrathi Sheila | President & CEO | 4048242 1.7865% | $0.76 | 1 | 0 | <0.0001% |
| Salter-Cid Luisa | Chief Scientific Officer | 206065 0.0909% | $0.76 | 0 | 3 | |
| Carter Laura | Chief Scientific Officer | 76263 0.0337% | $0.76 | 1 | 6 | <0.0001% |
| Milligan Sandra | director | 32000 0.0141% | $0.76 | 1 | 0 | |
| Cox Russell J. | director | 7200 0.0032% | $0.76 | 1 | 0 | +6.27% |
| Dupont Jakob | Chief Medical Officer | 0 0% | $0.76 | 0 | 2 |
Institutional Investor Ownership
| Nea Management Company Llc | $18.69M | 7 | 15.84M | 0% | +$0 | 0.09 | |
| Artal Group S A | $15.7M | 5.88 | 13.31M | +10.37% | +$1.47M | 0.07 | |
| The Vanguard Group | $13.88M | 5.2 | 11.76M | +1.1% | +$151,217.00 | <0.0001 | |
| Ecor1 Capital Llc | $10.85M | 4.07 | 9.2M | 0% | +$0 | 0.08 | |
| Octagon Capital Advisors LP | $10.84M | 4.06 | 9.19M | 0% | +$0 | 0.06 | |
| Fidelity Investments | $9.66M | 3.62 | 8.19M | -33.23% | -$4.81M | <0.01 | |
| Arch Venture Management Llc | $9.51M | 3.56 | 8.06M | 0% | +$0 | 0.47 | |
| Millennium Management LLC | $7.66M | 2.87 | 6.5M | +53.75% | +$2.68M | 0.01 | |
| Palo Alto Investors Lp | $7.54M | 2.83 | 6.39M | +7.26% | +$510,806.69 | 0.85 | |
| Farallon Capital | $7.23M | 2.71 | 6.13M | 0% | +$0 | 0.05 | |
| Silverarc Capital Management Llc | $7.23M | 2.71 | 6.13M | 0% | +$0 | 0.07 | |
| Samsara Biocapital Llc | $7.23M | 2.71 | 6.13M | 0% | +$0 | 1.13 | |
| Eversept Partners LP | $7.07M | 2.65 | 5.99M | -6.81% | -$517,126.74 | 0.54 | |
| Hillhouse Capital Advisors Ltd | $5.87M | 2.2 | 4.97M | 0% | +$0 | 0.13 | |
| PLATINUM INVESTMENT MANAGEMENT LTD | $5.54M | 2.08 | 4.69M | -32.5% | -$2.67M | 0.07 | |
| Morgan Stanley | $5.12M | 1.92 | 4.34M | -22.16% | -$1.46M | <0.0001 | |
| Madison Avenue Partners, LP | $4.89M | 1.83 | 4.14M | -18.08% | -$1.08M | 0.8 | |
| Citadel Advisors LLC | $4.57M | 1.71 | 3.87M | -36.9% | -$2.67M | <0.01 | |
| Deutsche Bank | $4.49M | 1.68 | 3.81M | 0% | +$0 | <0.01 | |
| Monashee Investment Management LLC | $4.08M | 1.53 | 3.46M | 0% | +$0 | 0.35 | |
| Ci Private Wealth Llc | $3.86M | 1.45 | 3.27M | +11.38% | +$394,520.06 | <0.01 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $3.86M | 1.44 | 3.27M | 0% | +$0 | 0.1 | |
| 683 Capital Management Llc | $3.83M | 1.44 | 3.25M | -1.95% | -$76,346.00 | 0.42 | |
| Federated Hermes | $3.85M | 1.39 | 3.13M | -2.29% | -$90,136.00 | 0.01 | |
| BlackRock | $3.65M | 1.37 | 3.09M | -8.56% | -$341,397.54 | <0.0001 | |
| T. Rowe Price | $3.41M | 1.28 | 2.89M | -21.76% | -$949,152.79 | <0.0001 | |
| Acadian Asset Management | $3.23M | 1.21 | 2.74M | +51.59% | +$1.1M | 0.01 | |
| Goldman Sachs | $3.18M | 1.19 | 2.69M | -1.18% | -$38,097.48 | <0.01 | |
| Opaleye Management Inc | $2.88M | 1.08 | 2.44M | -18.18% | -$639,667.46 | 0.64 | |
| Laurion Capital Management LP | $2.72M | 1.02 | 2.3M | New | +$2.72M | 0.02 | |
| Citigroup | $2.7M | 1.01 | 2.29M | +34.15% | +$687,165.82 | <0.01 | |
| Geode Capital Management | $2.7M | 1.01 | 2.28M | +0.47% | +$12,620.59 | <0.0001 | |
| Susquehanna International Group | $2.14M | 0.8 | 1.81M | +262.61% | +$1.55M | <0.01 | |
| Jacobs Levy Equity Management | $1.93M | 0.72 | 1.63M | -22.3% | -$553,377.48 | 0.01 | |
| DAFNA Capital Management, LLC | $1.66M | 0.62 | 1.41M | -4.53% | -$78,812.19 | 0.04 | |
| Driehaus Capital Management LLC | $1.61M | 0.6 | 1.37M | New | +$1.61M | 0.02 | |
| Charles Schwab | $1.48M | 0.55 | 1.25M | +2.7% | +$38,863.31 | <0.0001 | |
| Marshall Wace | $1.45M | 0.54 | 1.23M | +21.26% | +$254,835.32 | <0.01 | |
| Two Sigma Advisers LP | $1.37M | 0.51 | 1.16M | +5.44% | +$70,682.00 | <0.01 | |
| Sphera Fund | $1.21M | 0.45 | 1.03M | -23.24% | -$366,928.04 | 0.01 | |
| Two Sigma | $954,350.00 | 0.36 | 808,771 | -20.88% | -$251,918.26 | <0.01 | |
| State Street | $813,316.00 | 0.31 | 689,251 | -3.41% | -$28,673.99 | <0.0001 | |
| Renaissance Technologies | $792,000.00 | 0.3 | 671,600 | -32.64% | -$383,736.74 | <0.01 | |
| Nantahala Capital Management Llc | $793,970.00 | 0.3 | 672,856 | 0% | +$0 | 0.04 | |
| Qube Research & Technologies | $778,428.00 | 0.29 | 659,685 | +188.59% | +$508,689.54 | <0.01 | |
| Highbridge Capital Management | $705,279.00 | 0.26 | 597,694 | -54.39% | -$841,084.04 | 0.02 | |
| D. E. Shaw & Co. | $699,609.00 | 0.26 | 592,889 | +16.97% | +$101,481.18 | <0.01 | |
| Hrt Financial Llc | $663,000.00 | 0.25 | 562,061 | +4,462.92% | +$648,469.84 | <0.01 | |
| Monaco Asset Management Sam | $656,080.00 | 0.25 | 556,000 | +98.57% | +$325,680.00 | 0.3 | |
| Td Asset Management Inc | $498,267.00 | 0.19 | 422,260 | -16.35% | -$97,397.24 | <0.0001 |